Key result
Chronic treatment with candesartan reversed metabolic variables, systolic blood pressure, cardiovascular remodeling, and inflammatory protein expression in a rat model of metabolic syndrome.
Why the study?
Does candesartan or 4OH-Tempol reduce vascular inflammation in a rat model of metabolic syndrome?
Does candesartan or 4OH-Tempol reduce vascular inflammation in a rat model of metabolic syndrome?
In a rat model of metabolic syndrome, RAS inhibition with candesartan was more effective than antioxidant therapy with 4OH-Tempol in reversing vascular inflammation and remodeling.
May support candesartan over antioxidants for vascular inflammation in metabolic syndrome models; hypothesis-generating, requires human trials before clinical adoption.
(1) This study aims to demonstrate the causal involvement of renin angiotensin system (RAS) and oxidative stress (OS) on vascular inflammation in an experimental model of metabolic syndrome (MS) achieved by fructose administration to spontaneously hypertensive rats (FFHR) during 12 weeks. (2) Chronic treatment with candesartan (C) (10 mg/kg per day for the last 6 weeks) or 4OH-Tempol (T) (10(-3) mmol/L in drinking water for the last 6 weeks) reversed the increment in metabolic variables and systolic blood pressure. In addition, chronic C treatment reverted cardiovascular remodeling but not T. (3) Furthermore, chronic treatment with C was able to completely reverse the expression of NF-κB and VCAM-1, but T only reduced the expression. C reduced the expression of proatherogenic cytokines as CINC2, CINC3, VEGF, Leptin, TNF-alpha, and MCP-1 and also significantly reduced MIP-3, beta-NGF, and INF-gamma in vascular tissue in this experimental model. T was not able to substantially modify the expression of these cytokines. (4) The data suggest the involvement of RAS in the expression of inflammatory proteins at different vascular levels, allowing the creation of a microenvironment suitable for the creation, perpetuation, growth, and destabilization of vascular injury.
No takes yet. Share an insight, caveat, or question.
Renna et al. (2013) studied Metabolic syndrome and vascular inflammation. Candesartan or 4OH-Tempol vs. Untreated experimental model was evaluated on Metabolic variables, systolic blood pressure, cardiovascular remodeling, and expression of inflammatory proteins. Chronic treatment with candesartan reversed metabolic variables, systolic blood pressure, cardiovascular remodeling, and inflammatory protein expression in a rat model of metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: